Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: GLP-1RA Feb 21 | 2019New Bydureon label update: EXSCEL now in US labelPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Feb 21 | 2019Biocorp/DreaMed Partnership; Abbott Libre and Valeritas V-Go RWEPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Feb 20 | 2019Connected Pens: New Novo and Abbott Partnership for Data IntegrationPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery Feb 20 | 2019Connected Pens: Novo Expanded Capability with Glooko; Biocorp/AgaMatrix PartnershipPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Feb 19 | 2019Medtronic Receives Breakthrough Device Designation; CY Q4 '18 (FY Q3 '19) Earnings UpdatePurchase Blast
$599
Posted in: DPP-IVi Feb 15 | 2019Merck Files 12 Lawsuits Over Generic Januvia/Janumet FilingsPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Feb 15 | 2019Thoughts on iPump Special ControlsPurchase Blast$599
Posted in: Insulin Delivery Feb 14 | 2019New iPump Pathway: Tandem t:slim X2 Approved as First Interoperable PumpPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, SGLT2i Feb 14 | 2019Farxiga LCM and Litigation Update; AZ Q4 '18 Earnings SummaryPurchase Blast
$599
Posted in: Glucagon Feb 12 | 2019Xeris Glucagon to be Branded "Gvoke"; Xeris Issues 5M Additional SharesPurchase Blast
$599
Posted in: Bolus Insulin, Insulin Delivery Feb 11 | 2019New Lilly and Novo uRAI pump trials: URLi ‘PRONTO-Pump-2’ and Fiasp in iLet Bionic PancreasPurchase Blast
$599
Posted in: SGLT2i Feb 08 | 2019Could Teva Generic Dapa Be Para III? Teva Receives Tentative FDA ApprovalPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, SGLT2i Feb 07 | 2019Sanofi Discontinues 2 Dual-Agonist Programs; Q4 '18 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, Insulin Delivery, SGLT2i Feb 06 | 2019No REWIND PRV Mentioned; Lilly Q4 '18 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Other Feb 05 | 2019Lilly to use PRV for REWIND? Novo Q4 ’18 London earnings updatePurchase Blast
$599
Posted in: Insulin Delivery Feb 05 | 2019BD CY Q4 '18 (FY Q1 '19) Earnings UpdatePurchase Blast
$599
Posted in: Insulin Delivery Feb 04 | 2019JDRF Criticizes Medtronic/UHC For Reducing Patient ChoicePurchase Blast
$599
Posted in: Glucose Monitoring Feb 04 | 2019Senseonics/Roche Renew Distribution Agreement; Acquisition UnlikelyPurchase Blast
Get the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
